LIDDS Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

LIDDS şirketinin toplam hissedar öz sermayesi SEK7.7M ve toplam borcu SEK0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK10.5M ve SEK2.8M dir.

Anahtar bilgiler

Borç/özkaynak oranı

SEK 0

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 8.01m
Eşitlik	SEK 7.72m
Toplam yükümlülükler	SEK 2.81m
Toplam varlıklar	SEK 10.53m

Son finansal sağlık güncellemeleri

Recent updates

Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

May 26

Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

Dec 15

Will LIDDS (STO:LIDDS) Spend Its Cash Wisely?

Jul 19

Here's Why We're Not Too Worried About LIDDS' (STO:LIDDS) Cash Burn Situation

Mar 08

We're Not Very Worried About LIDDS' (STO:LIDDS) Cash Burn Rate

Nov 23

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: LIDDS 'nin kısa vadeli varlıkları ( SEK9.1M ) kısa vadeli yükümlülüklerini ( SEK1.9M ) aşıyor.

Uzun Vadeli Yükümlülükler: LIDDS şirketinin kısa vadeli varlıkları ( SEK9.1M ) uzun vadeli yükümlülüklerini ( SEK900.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: LIDDS borçsuzdur.

Borcun Azaltılması: LIDDS un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: LIDDS şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: LIDDS un, serbest nakit akışı her yıl % 1 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

LIDDS Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

Will LIDDS (STO:LIDDS) Spend Its Cash Wisely?

Here's Why We're Not Too Worried About LIDDS' (STO:LIDDS) Cash Burn Situation

We're Not Very Worried About LIDDS' (STO:LIDDS) Cash Burn Rate

Recent updates

LIDDS AB (publ) to Report Fiscal Year 2024 Results on Feb 20, 2025

LIDDS AB (publ) to Report Nine Months, 2024 Results on Nov 21, 2024

LIDDS AB (publ) to Report First Half, 2024 Results on Aug 28, 2024

LIDDS AB (publ) Announces CFO Changes, Effective 1 September 2024

New major risk - Shareholder dilution

LIDDS AB (publ), Annual General Meeting, May 27, 2024

LIDDS AB (publ) (OM:LIDDS) completed the acquisition of Noviga Research AB.

LIDDS AB (publ) (OM:LIDDS) signed an agreement to acquire Noviga Research AB.

LIDDS AB (publ) (OM:LIDDS) signed an agreement to acquire Noviga Research AB.

LIDDS AB (publ) Approves Board Elections

LIDDS AB (publ) to Report Fiscal Year 2023 Final Results on Apr 23, 2024

Lidds AB (Publ) Announces Resignation of Daniel Lifveredson from Board of Directors

LIDDS AB (publ) to Report Q1, 2024 Results on May 15, 2024

First half 2023 earnings released: kr0.29 loss per share (vs kr0.58 loss in 1H 2022)

LIDDS AB (publ) Announces CEO Changes

New major risk - Financial position

First quarter 2023 earnings released: kr0.29 loss per share (vs kr0.29 loss in 1Q 2022)

Full year 2022 earnings released: kr1.07 loss per share (vs kr1.16 loss in FY 2021)

LIDDS AB (publ) to Report Fiscal Year 2022 Results on Apr 25, 2023

Third quarter 2022 earnings released: kr0.23 loss per share (vs kr0.26 loss in 3Q 2021)

Second quarter 2022 earnings released: kr0.29 loss per share (vs kr0.32 loss in 2Q 2021)

LIDDS AB (publ) to Report Fiscal Year 2022 Results on Feb 24, 2023

High number of new directors

LIDDS AB (publ) Announces CEO Changes

LIDDS Patent Covering the NanoZolid® Production Process Granted in Israel

LIDDS AB (publ) Announces Board Changes

Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

First quarter 2022 earnings: EPS and revenues miss analyst expectations

LIDDS AB (publ) to Report Q2, 2022 Results on Aug 25, 2022

No independent directors

LIDDS AB (publ) announced that it expects to receive SEK 40.8 million in funding from Nice & Green SA

LIDDS AB Next Step with Nanozolid® Formulated Docetaxel

LIDDS AB Announces Positive Topline Results from the Phase I Dose-Escalating Study of NanoZolid-Formulated Docetaxel

Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

Will LIDDS (STO:LIDDS) Spend Its Cash Wisely?

Here's Why We're Not Too Worried About LIDDS' (STO:LIDDS) Cash Burn Situation

Director recently bought kr159k worth of stock

LIDDS AB (publ) Enters R&D Agreement with Potential Exclusive, Global Product License Option

New 90-day low: kr13.50

LIDDS AB (publ) and Pharmidea Signs Manufacturing Agreement

LIDDS Files Patent Application for Method to Treat Brain Cancer with Intratumoral Depot Injections

LIDDS AB (publ) Provides Update on Chinese Conditional Market Approval (CMA) for Liproca® Depot

LIDDS AB (publ) Announces Management Changes, Effective April 19, 2021

We're Not Very Worried About LIDDS' (STO:LIDDS) Cash Burn Rate

New 90-day low: kr13.00

New 90-day low: kr13.10

LIDDS AB (publ) Announces Data on Liproca Depot from Open Label Extension Study

New 90-day high: kr16.15

LIDDS AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 37.083996 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin